Theravance Biopharma (TBPH) Asset Writedowns and Impairment (2015 - 2024)
Theravance Biopharma (TBPH) posted quarterly Asset Writedowns and Impairment of $1.6 million for Q3 2024, up 1510.31% quarter-over-quarter from $97000.0 in Q4 2017.
Powered by 
Analysis
Theravance Biopharma (TBPH) Asset Writedowns and Impairment (2015 - 2024) Analysis & Trends
Theravance Biopharma (TBPH) has reported Asset Writedowns and Impairment for 4 consecutive years, with $1.6 million the latest figure, recorded in Q3 2024.
- In Q3 2024, Asset Writedowns and Impairment changed N/A year-over-year to $1.6 million; the TTM figure through Dec 2024 stood at $9.7 million (changed N/A YoY), while the FY2024 annual figure was $4.5 million, changed N/A from the prior year.
- Asset Writedowns and Impairment improved to $1.6 million in Q3 2024 per TBPH's latest filing, from $97000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $1.6 million in Q3 2024 and bottomed at $1.6 million in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Theravance Biopharma | 882.99 Mn | 495.33 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | 1.56 Mn |
| Dec 31, 2017 | 97,000.00 |
| Sep 30, 2017 | 8.00 Mn |
| Jun 30, 2017 | 642,000.00 |
| Dec 31, 2016 | 184,000.00 |
| Jun 30, 2016 | 109,000.00 |
| Mar 31, 2016 | 10,000.00 |
| Dec 31, 2015 | 2.02 Mn |
| Mar 31, 2015 | 79,000.00 |